ArticleIn vivo (Athens, Greece)
The Impact of Peripheral Eosinophil Counts and Eosinophil to Lymphocyte Ratio (ELR) in the Clinical Course of COVID-19 Patients: A Retrospective Study.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical applications of blood cell ratios in veterinary hematology: From diagnosis to prognosis.Veterinary and animal science · 2026Review
- Association between eosinophil counts and outcomes of severe coronavirus disease 2019 in elderly asthma patients: a prospective cohort study.Journal of thoracic disease · 2025Article
- Exploring the correlation between eosinophils with clinical risk of severe pneumonia based on MIMIC-IV data.Scientific reports · 2025Article
- Circulating white blood cell traits and prolonged night shifts: a cross-sectional study based on nurses in Guangxi.Scientific reports · 2024Article
- Temporal trends in laboratory parameters in survivors and non‑survivors of critical COVID‑19 illness and the effect of dexamethasone treatment.Biomedical reports · 2024Article
- Article
- Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study.Experimental and therapeutic medicine · 2022Article
- Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance.Experimental and therapeutic medicine · 2022Article
- Immature granulocytes: Innovative biomarker for SARS‑CoV‑2 infection.Molecular medicine reports · 2022Article
- Hematological Abnormalities in COVID-19 Disease: Association With Type I Interferon Pathway Activation and Disease Outcomes.Frontiers in medicine · 2022Article
- Asymptomatic SARS-CoV-2 infection in an unvaccinated 97-year-old woman: A case report.Biomedical reports · 2021Article
- Acute Inflammatory Mediators in Young Adult Patients with COVID-19 in Mexico.Pathogens (Basel, Switzerland) · 2021Article
- Emerging Evidence for Pleiotropism of Eosinophils.International journal of molecular sciences · 2021Review
- Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.International journal of molecular sciences · 2021Review
- Eosinophil: A Nonnegligible Predictor in COVID-19 Re-Positive Patients.Frontiers in immunology · 2021Article
- Prognostic Superiority of the White Cell-to-Lymphocyte Ratio (WLR) in Predicting Overall Survival in Patients With Gliomas.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimEosinophils are blood cells responsible for response against parasites and allergens. Eosinophil to lymphocyte ratio (ELR) is a biomarker for inflammatory conditions. Our aim was to evaluate the role of eosinophils and ELR in COVID-19 patients. PATIENTS AND
methodsThe study included 96 patients hospitalized with COVID-19. They were classified into moderate to severe cases and critical cases. Eosinophils and ELR were determined in both groups, in patients that died or survived and were correlated to duration of hospitalization.
resultsThere was a statistically significant decrease in eosinophils and ELR between patients that died and patients that survived (p<0.05), and in mean values of the two biomarkers (p<0.05 for eosinophils and p<0.05 for ELR) between patients hospitalized for more or less than 15 days among those with moderate to severe disease.
conclusionLower eosinophil counts and ERL could probably predict worse outcome in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.